Form D · Biotechnology
Aditxt, Inc.
Richmond, VA · CIK 0001726711
Offering snapshot reported Jan 23, 2024 · SEC filing
- Reported sold
- $6M Offering amount: $6M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 29, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 23, 2024 | Initial | $6,000,000 | No comparison | 1 | SEC filing |
| Sep 20, 2023 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
| Aug 17, 2022 | Initial | $2,033,333 | No comparison | 6 | SEC filing |
| Jan 26, 2021 | Initial | $6,000,000 | No comparison | 1 | SEC filing |
| Dec 26, 2018 | Initial | $109,800 | No comparison | 4 | SEC filing |
| Mar 29, 2018 | Initial | $262,500 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $495K
- Finders' fees
- $0
- Form D file number
- 021-503204
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| H.C. Wainwright & Co., LLC | 375 |
Source: Form D, filed Jan 23, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Rowena Albanna | Executive |
| Amro Albanna | Director, Executive |
| Laura E. Anthony | Director |
| Leonard Bailey | Director |
| Brian Brady | Director |
| Thomas Farley | Executive |
| Namvar Kiaie | Director |
| Charles Athle Nelson | Director |
| Corinne Pankovcin | Executive |
| Jeffrey Runge | Director |
| Shahrokh Shabahang | Director, Executive |
| Matthew Shatzkes | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
737 N. Fifth Street Suite 200
Richmond, VA, 23219
Richmond, VA, 23219